Flerie Invest successfully completed a reverse acquisition of Flerie AB, aiming to strengthen its financial position in the biotechnology sector.

Target Information

Flerie Invest recently engaged in a significant transaction involving Flerie AB, formerly known as InDex Pharmaceuticals. During the quarterly period from April to June 2024, the company's net assets were valued at 4,380 million SEK, equivalent to an asset value of 56.10 SEK per share. The adjusted asset value per share was marginally lower at 57.41 SEK. The company saw a slight decline of 0.3% in its asset value per share, while the adjusted change reflected a modest increase of 2.1%.

As of the first half of 2024, Flerie Invest has reported changes in its portfolio, with a significant value adjustment of 172 million SEK reflecting a 6.2% growth in the company's actual value of shares and holdings. However, the net income for this period saw a deficit of 47 million SEK compared to a previous loss of 38 million SEK.

Industry Overview in Sweden

The pharmaceutical and biotechnology sectors in Sweden are recognized as innovative fields contributing significantly to the economy. With a concentration of life sciences research and a robust ecosystem of co